MTHFR Genotype

The two variants this test reports are ordinary genetic variation, not a disease. About 10 to 15 percent of people of European ancestry carry two copies of the most-studied one, and more than a quarter of Hispanic people do. A variant that common is unlikely to be doing much harm on its own.

That does not make the result useless. It tells you something real about how your body handles folate, and in a few specific situations it changes what you should do. The trick is knowing which claims about it hold up and which are marketing.

What the Gene Actually Does

MTHFR (methylenetetrahydrofolate reductase) is an enzyme your body makes in nearly every tissue. Its job is to convert one form of folate into another: the form that circulates in your blood and gets used to recycle homocysteine back into methionine. Homocysteine is an amino acid that builds up when this recycling slows down.

Methionine then becomes the molecule your cells use to add chemical tags to DNA and proteins. So this one enzyme decides whether folate goes toward building DNA or toward that tagging work. It needs riboflavin (vitamin B2) as a helper molecule to work at all, which matters later.

The test looks at two spots in the gene. C677T is the one that matters more. The enzyme it produces is less stable when warmed, which is where the old name for it, thermolabile, came from. A1298C has a milder effect. At each spot you inherit one copy from each parent, so you get one of three results: two normal copies, one variant copy, or two variant copies.

What Each Result Means

Two copies of C677T, reported as TT, leave you with roughly 30 percent of normal enzyme activity. That sounds alarming until you see what it does in practice: people with TT have modestly lower blood folate and somewhat higher homocysteine than people with two normal copies. Inside red blood cells the mix of folate forms shifts as well, with less of it held in the active circulating form.

The other results carry less weight. The American College of Medical Genetics and Genomics has stated plainly that carrying one C677T copy, two A1298C copies, or one of each currently appears unlikely to be clinically significant. If that is your result, nothing about your medical care changes.

How much the TT genotype affects you depends on how much folate you get. Where grain products are fortified with folic acid, as in the United States, the metabolic gap between TT and normal genotypes narrows considerably. Blood folate in TT individuals runs about 13 to 20 percent lower than in people with two normal copies, not catastrophically lower.

Blood Pressure and Riboflavin

This is the most interesting finding about the TT genotype and the one most people have never heard. Riboflavin, an inexpensive B vitamin, appears to lower blood pressure in people with this genotype while doing nothing measurable in everyone else. The signal is real but the evidence behind it is still thin, and that qualification matters.

A 2025 Cochrane review pooled the trials. Across all participants riboflavin did not lower blood pressure: systolic fell about 2 mmHg, with a range that included no effect at all. Within the TT subgroup it fell about 4.8 mmHg, but the comparison between genotypes did not reach statistical significance, every included trial was judged at high risk of bias, and the reviewers rated the certainty of the evidence as very low. The dose in the underlying Irish trials was 1.6 mg of riboflavin a day for 16 weeks; the review found no clear difference by dose. A four-year follow-up in TT individuals who already had cardiovascular disease reported larger falls, about 9 mmHg systolic and 6 diastolic.

The mechanism explains why any effect would be genotype-specific. The C677T variant makes the enzyme hold its riboflavin-derived helper molecule less tightly, and supplying more riboflavin partly compensates. Observational work has also found higher hypertension risk in TT individuals specifically when riboflavin status is poor. Taken together this is a plausible example of a genetic result changing what you take, not a settled one, and it only applies if you are TT.

Stroke and Heart Disease

Here the evidence splits in a way that confused the field for two decades, and the resolution is worth understanding.

In a study of 156,253 Chinese adults followed for 12 years, TT carried about 13 percent higher risk of any stroke compared to the normal genotype, with bleeding strokes showing the larger increase at about 24 percent. China does not fortify its grain supply with folic acid. A pooled Danish study of 13,748 adults followed about eleven years found no stroke association at all and no difference in overall death rate, though coronary heart disease risk was higher.

The reconciliation: this is not a fixed risk that travels with the gene. It is a gene-nutrient interaction. A meta-analysis that tested this directly found the stroke association appears only in low-folate regions and disappears where folic acid fortification exists. The gene has not changed. The food supply has.

For coronary heart disease the story is different again. The largest analysis, covering 48,175 cases and 67,961 controls and including previously unpublished datasets, found no association at all. Published studies had shown a modest 15 percent increase. That gap between published and unpublished results is the signature of publication bias: studies finding nothing went into file drawers.

Cancer: Mostly Nothing, Sometimes Protective

The TT genotype slightly lowers colorectal cancer risk. A 2025 meta-analysis found about 11 percent lower risk in TT than in the normal genotype, with the protection strongest when folate intake is high. That is the opposite of what a "defective enzyme" framing would predict.

The framework that makes both findings consistent: this variant does not make you globally healthier or sicker. It shifts how your cells allocate folate. Pushing folate toward DNA building rather than chemical tagging appears to protect against colorectal cancer while leaving less capacity for homocysteine recycling. Different tissues, different consequences, same enzyme.

Across cancers overall the effect is close to nothing. A meta-analysis covering roughly 75,000 cancer cases found about 7 percent higher risk of any cancer, and the prospective Danish cohort reported in the same paper found no difference at all. In those pooled case-control comparisons gastric cancer ran about 40 percent higher and esophageal cancer about 77 percent higher, the one site where the increase was sizable rather than slight. Prostate cancer showed no overall association, and in Asian populations TT was linked to lower risk.

What This Test Does Not Tell You

Three claims come up constantly and none of them survive the evidence.

• Blood clots: MTHFR variants do not belong in a clotting workup. ACMG, the American College of Obstetricians and Gynecologists, the American Society of Hematology, and the British Committee for Standards in Haematology all say the same thing. Recent meta-analyses show no meaningful link to clots in the veins. The tests that do matter for clotting are Factor V Leiden, prothrombin G20210A, and the protein C, protein S, and antithrombin assays.
• Recurrent miscarriage: prospective studies found no association between MTHFR variants and fetal loss, and trials of blood thinners in women with these variants and pregnancy loss showed no benefit. ACOG recommends against testing for this reason.
• Unexplained symptoms: ACMG specifically warns that medical problems are often incorrectly blamed on a positive MTHFR result. Fatigue, anxiety, brain fog, and weight changes have real causes worth investigating properly, and a common genetic variant is rarely one of them.

Severe Deficiency Is a Different Condition

There is a rare inherited disorder caused by mutations that nearly eliminate MTHFR enzyme function. Homocysteine climbs high enough to spill into the urine, and it brings developmental delay, neurologic problems, clots, and skeletal abnormalities, usually starting in childhood. This is not what the common variant panel detects, and carrying C677T or A1298C does not put you anywhere near that territory.

A One-Time Result You Use for Decades

Your genotype will not change. There is no trend to track, no retesting schedule, and no reason to repeat this test unless the original call itself is in question. One result, for life.

What does need tracking is the metabolic consequence, and that is where your attention should go. If you are TT, homocysteine is the number worth watching, along with folate, vitamin B12, and vitamin B6, since a shortfall in any of them pushes homocysteine up independently of your genotype. Get a baseline of all four, recheck in three to six months if you change anything, then at least annually.

If you are TT and your blood pressure runs high, that combination is the one worth acting on. Riboflavin is cheap and low-risk, and the trial evidence, thin as it is, points specifically at your genotype.

What an Unexpected Result Should Make You Do

A TT result with normal homocysteine means you can stop thinking about this. ACMG says such people can be reassured there is no evidence of increased clotting or pregnancy loss risk tied to their genotype.

A TT result with high homocysteine is the combination worth a workup, and the workup is not genetic. Check folate, B12, and B6 first, since a shortfall in any is common and correctable. Check kidney function, because impaired kidneys raise homocysteine on their own. Thyroid matters too. If homocysteine comes back extremely high, far beyond what a vitamin shortfall produces, that is a different situation entirely and warrants testing for the rare severe mutations, which is a separate test from this panel.

If you are about to start methotrexate for cancer, psoriasis, or rheumatoid arthritis, your MTHFR genotype is one of the few settings where it may inform dosing. Bring the result to the prescriber.

If you have had a blood clot, order the thrombophilia panel that actually matters and involve a hematologist. Your MTHFR result contributes nothing there, and letting it stand in for a real workup is the specific error the guidelines were written to prevent.

When a Genetic Result Can Mislead

Genotype tests do not drift with illness, diet, or time of day, but they have their own failure modes.

• Panel coverage: this test looks for two specific spots in the gene. A result showing neither variant does not rule out rarer changes elsewhere in MTHFR, including the ones that cause severe deficiency. Reading the whole gene would pick those up; this test does not look for them.
• Ancestry matters: the frequency of these variants differs sharply by population, and so does the evidence base. The stroke signal comes largely from Chinese and other low-folate populations. ACMG specifically cautions against applying conclusions across ancestry groups without considering diet.
• Consumer versus clinical testing: direct-to-consumer reports often present these variants with more urgency than the evidence supports. If your result came from a consumer service and would change a medical decision, confirming it through a clinical laboratory is reasonable.
• Your diet changes what the result means: the same genotype carries different consequences depending on your folate intake. In a fortified food supply, the metabolic effect is much smaller than the older literature suggests.